The effect of an electronic medicine dispenser on diversion of buprenorphine-naloxone—experience from a medium-sized Finnish city

Uosukainen, Hanna; Pentikäinen, Hannu; Tacke, Ulrich

doi:10.1016/j.jsat.2013.01.003

Cited by 14 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously mentioned, buprenorphine adherence has been associated with increased retention among opioid dependent youth (Warden et al, 2012). For this reason, using remote technology to promote buprenorphine adherence, such as secure electronic pill dispensers (Uosukainen, Pentikainen, & Tacke, 2013), offers promise. Development of specific behavioral therapy manuals targeting emerging adult developmental tasks may be helpful.…”

Section: Discussionmentioning

confidence: 99%

Emerging adult age status predicts poor buprenorphine treatment retention

Schuman‐Olivier

Weiss

Hoeppner

et al. 2014

Journal of Substance Abuse Treatment

110

View full text Add to dashboard Cite

Emerging adults (18–25 years old) are often poorly retained in substance use disorder treatment. Office-based buprenorphine often enhances treatment retention among people with opioid dependence. In this study, we examined the records of a collaborative care buprenorphine treatment program to compare the treatment retention rates of emerging adults versus older adults. Subjects were 294 adults, 71 (24%) aged 18–25, followed in treatment with buprenorphine, nurse care management, and an intensive outpatient program followed by weekly psychosocial treatment. Compared to older adults, emerging adults remained in treatment at a significantly lower rate at 3 months (56% versus 78%) and 12 months (17% versus 45%), and were significantly more likely to test positive for illicit opioids, relapse, or drop out of treatment. Further research into factors associated with buprenorphine treatment retention among emerging adults is needed to improve treatment and long-term outcomes in this group.

show abstract

Section: Discussionmentioning

confidence: 99%

Emerging adult age status predicts poor buprenorphine treatment retention

Schuman‐Olivier

Weiss

Hoeppner

et al. 2014

Journal of Substance Abuse Treatment

110

View full text Add to dashboard Cite

show abstract

“…This electronic device may indeed have some curbing effects and ensure more safety with unsupervised medication dispensing and intake. 67 However, the device alone would not address the root problem, nor could it be the main approach to address the issue of diversion.…”

Section: Discussionmentioning

confidence: 99%

Buprenorphine Prescribing: To Expand or Not to Expand

Shorter

Kosten

2016

Journal of Psychiatric Practice

View full text Add to dashboard Cite

As a result of the prescription opioid epidemic in the United States, there has been an increasing need for effective treatment interventions, both pharmacologic and non-pharmacologic. Buprenorphine has emerged as a critical component of the treatment of opioid use disorder, yet its adoption has not been without some concerns. This article first reviews the pharmacology, clinical use, and US legislative action related to buprenorphine, followed by a discussion of the misuse and diversion of buprenorphine in the United States as well as internationally. We then explore the impact of buprenorphine abuse as well as discussing strategies for its reduction, including changes in policy, prescription and pharmacy monitoring, and continuing medical education for guiding and improving clinical practice.

show abstract

“…Second, we leveraged technology to support buprenorphine dispensing and daily monitoring. While the Med-O-Wheel has begun to be used clinically in Finland where it is manufactured (Tacke et al, 2009; Uosukainen et al, 2013), this is the first study to our knowledge to rigorously evaluate its utility as a component of buprenorphine treatment for opioid dependence. With regard to the m Health monitoring, IVR systems seem uniquely compatible with IBT and with opioid-dependent patients more generally (Moore et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Bridging waitlist delays with interim buprenorphine treatment: Initial feasibility

Sigmon

Meyer

Hruska

et al. 2015

Addictive Behaviors

View full text Add to dashboard Cite

Despite the effectiveness of agonist maintenance for opioid dependence, individuals can remain on waitlists for months, during which they are at significant risk for morbidity and mortality. Interim dosing, consisting of daily medication without counseling, can reduce these risks. In this pilot study, we examined the initial feasibility of a novel technology-assisted interim buprenorphine treatment for waitlisted opioid-dependent adults. Following buprenorphine induction during Week 1, participants (n=10) visited the clinic at Weeks 2, 4, 6, 8, 10 and 12 to ingest their medication under staff observation, provide a urine specimen and receive their remaining doses via a computerized Med-O-Wheel Secure device. They also received daily monitoring via an Interactive Voice Response (IVR) platform, as well as random call-backs for urinalysis and medication adherence checks. The primary outcome was percent of participants negative for illicit opioids at each 2-week visit, with secondary outcomes of past-month drug use, adherence and acceptability. Participants achieved high levels of illicit opioid abstinence, with 90% abstinent at the Week 2 and 4 visits and 60% at Week 12. Significant reductions were observed in self-reported past-month illicit opioid use (p<.001), opioid withdrawal (p<.001), opioid craving (p<.001) and ASI Drug composite score (p=.008). Finally, adherence with buprenorphine administration (99%), daily IVR calls (97%) and random call-backs (82%) was high. Interim buprenorphine treatment shows promise for reducing patient and societal risks during delays to conventional treatment. A larger-scale, randomized clinical trial is underway to more rigorously examine the efficacy of this treatment approach.

show abstract

The effect of an electronic medicine dispenser on diversion of buprenorphine-naloxone—experience from a medium-sized Finnish city

Cited by 14 publications

References 39 publications

Emerging adult age status predicts poor buprenorphine treatment retention

Emerging adult age status predicts poor buprenorphine treatment retention

Buprenorphine Prescribing: To Expand or Not to Expand

Bridging waitlist delays with interim buprenorphine treatment: Initial feasibility

Contact Info

Product

Resources

About